NovaBiotics

company

About

NovaBiotics Ltd is a clinical-stage biotechnology company.

  • 11 - 50

Details

Last Funding Type
Angel
Last Funding Money Raised
£1.10M
Industries
Biotechnology,Clinical Trials,Medical,Therapeutics
Founded date
Jan 1, 2004
Number Of Employee
11 - 50
Operating Status
Active

NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®).

NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
£4.10M
NovaBiotics has raised a total of £4.10M in funding over 2 rounds. Their latest funding was raised on Mar 3, 2016 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 3, 2016 Series Unknown £3M 1 Detail
Jun 1, 2009 Angel £1.10M 1 Aurora Private Equity Detail

Investors

Number of Lead Investors
Number of Investors
1
2
NovaBiotics is funded by 2 investors. Aurora Private Equity and Grampian Biopartners are the most recent investors.
Investor Name Lead Investor Funding Round
Aurora Private Equity Yes Angel
Grampian Biopartners Series Unknown